AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-K$AZR

Azora Therapeutics Reports 2026 Third Quarter Financial Results

Azora Therapeutics, Inc. (DE) (AZR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Azora Therapeutics Reports 2026 Third Quarter Financial Results and Provides Business Update Azora Therapeutics commenced trading on Nasdaq as “AZR” New executive team and Board of Directors appointed AT177 IND submission and Phase 1a initiation on track for the firs

Event · Earnings
Original reporting
SEC EDGAR 8-K
Published Nov 12, 2026, 9:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AZR
Bearish
high confidence
Mentioned
$AZR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AZRBearishMed
01

Why it matters

The Q3 loss and cash position suggest short‑term downside, but the IND filing timeline and experienced team could support longer‑term upside.

02

Market read

First‑report 8‑K provides fresh financial and operational data for a newly listed biotech, creating immediate trading relevance.

03

What to watch

The recent board and executive appointments bring deep experience in FDA approvals, which may reduce execution risk for AT177.

Relevance 7/10Novelty 8/10Timing: after‑hours today

Background

Azora Therapeutics, formerly Adial Pharmaceuticals, recently listed on Nasdaq under AZR and announced a name change, new leadership, and progress on its AT177 program.

Company-level read

Ticker impact

$AZRBearishHigh confidence
Context

Azora Therapeutics filed an 8‑K reporting Q3 2026 results, net loss of $64.6 M, cash $22 M, new executive team and IND filing plan for AT177.

Expected impact

downward pressure as investors price the large loss and dilution; potential upside if IND submission proceeds on schedule.

Evidence & confidence

First‑report of financials for a micro‑cap biotech; loss magnitude and cash position are material, but future trial milestones may limit downside.

Market effects

Sector

Highlights continued funding needs for early‑stage biotech companies developing novel oral therapies.

Regional

Limited to U.S. biotech sector; no broader market effect.

Global

Minimal; primarily relevant to investors tracking early‑stage biopharma pipelines.

Counterpoint

What could challenge this read

If the IND submission proceeds on schedule, the stock could rally on the upside potential of a first‑in‑class AhR agonist for ulcerative colitis.

Key entities

  • Executive
    Matt Davidson

    President and CEO, co‑founder of Azora.

  • Executive
    Celia Economides

    Chief Financial Officer.

  • Executive
    David Rubenstein, M.D., Ph.D.

    Chief Scientist, former lead on FDA‑approved AhR agonist.

Read at source← All news

Related articles

$TEOMedAI 8/10

Telecom Argentina Stet - France Telecom Q3 Earnings Call Highlights

Telecom Argentina (NYSE:TEO) reported Q3 capital expenditures of $350M, with net debt decreasing 9% YoY to $2.9B. 5G sites expanded to 1,900. Postpaid mobile lines grew 1% YoY, broadband increased 2.5%, and pay TV grew nearly 5%. EBITDA margin excluding TMA exceeded 42%. The company agreed to a $400M divestment with Metrotel, aiming for future integration.

finance.yahoo.com
LowAI 8/10

CoreWeave’s Results Foretell Impending Consolidation In AI Neocloud Sector

CoreWeave reported record Q3 revenue of $3.66B, up 168% YoY, and raised its full-year outlook. However, it also reported a net loss of $709M, $846M in interest expense, and plans $39B in 2026 capex. Its debt grew to $46.8B by Q3 2026. CoreWeave's growth relies on significant financing, raising concerns about the neocloud business model's sustainability and potential consolidation.

finance.yahoo.com
$CRDOMed

Credo Technology outpaces Broadcom in AI networking growth

Credo Technology Group reported fiscal 2026 revenue of $1.3B, up 206% YoY, with non-GAAP EPS rising 392% to $3.46. The company's growth is driven by AI networking products, including active electrical cables. Credo's stock gained 74% YTD. Broadcom's AI chip revenue grew 221% YoY to $16.7B in one quarter. Credo expects over 80% revenue growth in fiscal 2027, with optical revenue exceeding $600M.

cryptobriefing.com
$RYAAYMedAI 8/10

Wizz Air's Profit Fell 67%. Ryanair's Fell Just 15%

Wizz Air's H1 profit fell 67% to €108.1M on 14% revenue growth, while Ryanair's profit dropped 15% to €2.15B on 3% revenue growth. Wizz faced higher fuel costs and grounded aircraft, while Ryanair benefited from better fuel hedging and fleet management. Both airlines cited fuel costs as a major factor.

liveandletsfly.com
$ABBNYMed

ABB India Sets Order Record as Motilal Oswal Upgrades Shares

ABB India reported record quarterly orders of ₹4,733 crore, up from ₹3,030 crore a year earlier, with revenue growth of 19.4% and profit growth of 10.5%. Motilal Oswal upgraded the stock to Buy with a ₹8,200 target price, citing strong order intake and growth forecasts, despite margin pressures from higher costs and currency volatility.

econotimes.com